Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on June 29, 2015. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and board appointments rather than financial performance.
Material Changes
The material change reported is the appointment of Anders O. Härfstrand, M.D., Ph.D., as a director, effective June 29, 2015. In connection with this appointment, the following compensatory arrangements were established:
- Initial Option Grant: An option to acquire 30,000 ordinary shares under the 2012 Long Term Incentive Plan. The exercise price equals the last reported sale price on June 29, 2015. Vesting occurs in equal annual installments over three years, contingent on continuous service.
- Annual Cash Retainer: $50,000 per year, paid in quarterly installments.
- Annual Option Grant: An annual grant of an option to acquire 15,000 ordinary shares. The exercise price is set on the date of grant (the day following the annual general meeting). These options vest in full on the earlier of the first anniversary of the grant date or the day prior to the next annual general meeting.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document notes the execution of a standard Deed of Indemnification with the new director.
Investor Verification Checklist
- Verify the closing share price of Prothena Corporation plc on June 29, 2015, to determine the exercise price of the initial 30,000 share option grant.
- Confirm the vesting schedule and service conditions for the initial option grant versus the annual recurring grants.
- Review the press release filed as Exhibit 99.1 for additional context on Dr. Härfstrand's qualifications and the Board's rationale for the appointment.